Using a genetically engineered mouse model for BRCA1-deficient breast cancer, we investigated therapeutic strategies to overcome ABCG2-mediated resistance to clinically used topoisomerase I inhibitors. This evidence concerns the gene ABCG2 and breast carcinoma.